Dariusz Kowalski

MD, PhD, Prof

Maria Sklodowska-Curie National Research Institute of Oncology

Poland

Research Interests

Explore related searches

Professors in Poland Professors in Medical Imaging Medical Imaging professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dariusz Kowalski, MD, PhD, is a Professor at the Maria Sklodowska-Curie National Research Institute of Oncology in Poland. His research primarily focuses on advancements in the treatment and management of lung cancer and thymic carcinoids. Recent publications include comprehensive reviews and studies on immunotherapy, chemotherapy outcomes, and the effects of genetic mutations on treatment efficacy.

Articles (14)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (8)

Paweł Teterycz

Maria Sklodowska-Curie National Research Institute of Oncology

POLAND

View details

Kamila Wojas-Krawczyk

Medical University of Lublin

POLAND

View details

Ewa Kalinka

Polish Mother’s Memorial Hospital Research Institute

POLAND

View details

Maciej Strzemski

Associate professor; Member of the Council for Scientific Degrees in the field of pharmaceutical sciences

Medical University of Lublin

POLAND

View details

Silvia NOVELLO

Professor

Università degli Studi di Torino

ITALY

View details

Tomasz Kucharczyk

Medical University of Lublin

POLAND

View details

JULIEN MAZIERES

PROFESSOR

FRANCE

View details

Zsolt Horváth

Head of Department

Bács-Kiskun County Hospital

HUNGARY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dariusz Kowalski

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Effectiveness of First-Line Treatment with Anaplastic Lymphoma Kinase and ROS1 Protoncogene Inhibitors in Non-Small Cell Lung Cancer Patients—Real-World Evidence of Two Polish Cancer Centers

Recent Clinical and Molecular Advances in the Management of Thymic Carcinoids: A Comprehensive Review

Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study

Pulmonary Benign Metastasizing Leiomyoma in a Postmenopausal Woman: A Case Report and Review of the Literature

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study

Nivolumab or Atezolizumab in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer? A Prognostic Index Based on Data from Daily Practice

Performance-Status Deterioration during Sequential Chemo-Radiotherapy as a Predictive Factor in Locally Advanced Non-Small Cell Lung Cancer

Beta Blockers with Statins May Decrease All-Cause Mortality in Patients with Cardiovascular Diseases and Locally Advanced Unresectable Non-Small-Cell Lung Cancer after Chemoradiotherapy

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC

Savolitinib for non-small cell lung cancer

RET Proto-Oncogene—Not Such an Obvious Starting Point in Cancer Therapy

Efficacy of Immunotherapy in Second-Line Treatment of KRAS-Mutated Patients with Non-Small-Cell Lung Cancer—Data from Daily Practice

Do We Need TNM for Tracheal Cancers? Analysis of a Large Retrospective Series of Tracheal Tumors

Collaborators (8)

Paweł Teterycz

Kamila Wojas-Krawczyk

Ewa Kalinka

Maciej Strzemski

Silvia NOVELLO

Tomasz Kucharczyk

JULIEN MAZIERES

Zsolt Horváth

Make your next move.